DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
Provided By PR Newswire
Last update: Aug 13, 2024
- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
- Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design
Read more at prnewswire.com
